ipo
Stage
2
Investors
About
Ardelyx is a biopharmaceutical company focused on developing first-in-class medicines for patients with unmet medical needs, with pipeline programs and marketed therapies addressing chronic kidney disease with hyperphosphatemia and irritable bowel syndrome with constipation (IBS-C).
Explore ARDELYX's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.